百奥泰生物制药股份有限公司怎么样?
1个回答
2019-03-11 · 查企业,搜老板,找关系,就上企查查!
关注
展开全部
简介:百奥泰生物科技(广州)有限公司(Biothera Solutions, formerly as Sinoasis Pharma, Ltd.)致力于研究开发新型完全人源抗体或其衍生多肽药物,专注于用于治疗危及人类生命的重大疾病,包括癌症,心血管疾病。公司专有的人源抗体或功能域的筛选技术和高效抗体生产表达技术,能够快速地将基因组信息转换成完全人源的抗体治疗药物,从而大大提高抗体药物的发现和开发的效率。通过几年的努力,公司已有丰富的在研产品线,其中一个候选药已进入临床后期。 公司在由香港科技园承办的生物创业投资论坛会中荣获”最具潜力公司” (http://www.chinabiotoday.com/articles/20090504_2)。 由于发展需要,公司现增加多个挑战性的岗位,欢迎符合条件的有志者加盟。
Biothera Solutions Ltd (formerly as Sinoasis Pharma), an emerging biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancers, cardiovascular diseases, and other life threatening diseases. The Company's initial internal products are focused on targets with relative degree of validation and disease areas with proven market opportunities, the areas of cancers and coronary heart diseases, the leading causes of death in both China and developed countries. The Company has developed a suite of proprietary therapeutic antibody engineering and production technologies, including a highly efficient antibody production system in CHO cells in a scalable fed-batch culture environment. Our fully human antibody technology platforms are well positioned to not only develop therapeutics internally but also provide services for biotech and pharmaceutical companies, including antibody manufacturing in a cGMP complied facility. Today, with one candidate product in late stage clinical and several in research with great potential, there remains a lot of challenging tasks to be accomplished and rewarding opportunities for energetic individuals to join our team. Biothera Solutions provides a competitive benefit package.
法定代表人:易贤忠
成立日期:2003-07-28
注册资本:32000万元人民币
所属地区:广东省
统一社会信用代码:91440116751954446J
经营状态:在营(开业)企业
所属行业:科学研究和技术服务业
公司类型:股份有限公司(中外合资、未上市)
英文名:Bio-Thera Solutions, Ltd.
人员规模:100-499人
企业地址:广州高新技术产业开发区科学城开源大道11号A6栋第五层
经营范围:药品研发(人体干细胞、基因诊断与治疗技术除外);生物技术咨询、交流服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术开发服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);医学研究和试验发展(人体干细胞、基因诊断与治疗技术除外);生物药品制造;药品零售
Biothera Solutions Ltd (formerly as Sinoasis Pharma), an emerging biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancers, cardiovascular diseases, and other life threatening diseases. The Company's initial internal products are focused on targets with relative degree of validation and disease areas with proven market opportunities, the areas of cancers and coronary heart diseases, the leading causes of death in both China and developed countries. The Company has developed a suite of proprietary therapeutic antibody engineering and production technologies, including a highly efficient antibody production system in CHO cells in a scalable fed-batch culture environment. Our fully human antibody technology platforms are well positioned to not only develop therapeutics internally but also provide services for biotech and pharmaceutical companies, including antibody manufacturing in a cGMP complied facility. Today, with one candidate product in late stage clinical and several in research with great potential, there remains a lot of challenging tasks to be accomplished and rewarding opportunities for energetic individuals to join our team. Biothera Solutions provides a competitive benefit package.
法定代表人:易贤忠
成立日期:2003-07-28
注册资本:32000万元人民币
所属地区:广东省
统一社会信用代码:91440116751954446J
经营状态:在营(开业)企业
所属行业:科学研究和技术服务业
公司类型:股份有限公司(中外合资、未上市)
英文名:Bio-Thera Solutions, Ltd.
人员规模:100-499人
企业地址:广州高新技术产业开发区科学城开源大道11号A6栋第五层
经营范围:药品研发(人体干细胞、基因诊断与治疗技术除外);生物技术咨询、交流服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术开发服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);医学研究和试验发展(人体干细胞、基因诊断与治疗技术除外);生物药品制造;药品零售
AmBeed
2024-08-16 广告
2024-08-16 广告
AmBeed提供305 种库存Histamine Receptor抑制剂。组胺受体是G蛋白偶联受体(GPCR)家族的成员,包括H1、H2、H3和H4四种类型。它们具有七个跨膜螺旋结构,分布在不同细胞和组织中,如神经细胞、平滑肌细胞和免疫细胞...
点击进入详情页
本回答由AmBeed提供
推荐律师服务:
若未解决您的问题,请您详细描述您的问题,通过百度律临进行免费专业咨询